Published by Competition Law360 and Health Law360 on July 22, 2010.EU Regulatory Procedures In The Pharmaceutical Sector
By Marleen Van Kerckhove, Asim Varma and Marco Ramondino, Arnold & Porter LLP
Law360, New York (July 22, 2010) -- On July 1, 2010, the European Union’s General Court upheld a
2005 decision from the European Commission that found that AstraZeneca PLC had abused its
dominant position by preventing or delaying the marketing of a generic version of its Losec
(omeprazole) product and hindering parallel imports of Losec capsules in certain countries. Losec is a
proton pump inhibitor used in the treatment of acid-related gastric diseases.
In 2005 the EC had found that AstraZeneca had abused its dominant position by: providing
deliberately misleading information to patent agents, national patent offices and national courts in an
attempt to acquire or preserve supplementary protection certificates to which AstraZeneca was not
entitled or to which it was entitled for a shorter duration, in order to keep out generic competition;
and deregistering the marketing authorizations for Losec capsules in certain countries, in combination
with the substitution on those markets of an advanced form of tablet presentation (Losec MUPs) in
The European Commission imposed a total fine of €60 million on AstraZeneca on account of the
AstraZeneca appealed the decision, contesting the commission’s findings on market definition,
Although the specific abuses at issue here took place in the context of the legal uncertainty
surrounding the regulations on eligibility for SPCs and the effect of deregistration of marketing
authorizations, which has since been clarified in case law and through regulatory reform, the judgment
provides important guidance for pending and future cases before the EC on hindering competitors
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
through the use of regulatory procedures, an area that is under increased scrutiny from the EC
following its recent sector inquiry into the pharmaceutical sector.
It is also the first EU precedent in the pharmaceutical sector to provide guidance on defining markets
and determining market power in abusive conduct cases.
Misrepresentations before patent offices and misuse of regulatory procedures for the approval of drugs
have previously been held to be antitrust violations by U.S. courts and by the Federal Trade
The Market Definition
One of the cornerstones of the decision is the commission’s position that PPIs and H2 blockers, drugs
also used in the treatment of acid-related gastric diseases but less advanced than PPIs, belonged to
The General Court noted that PPIs and H2 blockers were prescribed to treat the same conditions and
that both constituted first-line treatments. Still, it found that the commission had rightfully concluded
that H2 blockers did not represent a competitive constraint on PPIs because the greater effectiveness
of PPIs led to a difference in use between the two drugs, with PPIs being used to treat the severe
forms of gastrointestinal acid-related conditions and H2 blockers being used for the less severe forms
Furthermore, the General Court ruled that the slow transition of the market from H2 blockers to PPIs
did not indicate that H2 blockers were a competitive constraint on PPIs. The General Court considered
that this was the result of the normal caution that doctors have in prescribing a new drug, rather than
of the competitive interaction between PPIs and H2 blockers.
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
The General Court considered the fact that in the pharmaceutical sector prices are determined or
influenced by public authorities and as such may not constitute a useful indication of the degree of
competition between two products. This did not, however, affect its conclusion.
It held that the difference in absolute prices of PPIs and H2 blockers reflects to a large extent the
authorities’ perception of a factor also taken into consideration by the EC when defining a separate
market for PPIs, namely the greater therapeutic efficacy of PPIs in comparison with H2 blockers.
In addition, although the General Court recognized that the reimbursement levels granted to PPIs to a
large extent prevented the lower prices of H2 blockers from exercising a competitive constraint over
PPIs, the fact that the absence of competitive constraints may be due to the regulatory framework on
the market concerned did not in its view undermine the conclusion on market definition.The Findings on Dominance
The commission’s assessment of AstraZeneca’s dominance was challenged on appeal with respect to
five key factors: (i) AstraZeneca’s high market shares over a long period of time; (ii) AstraZeneca’s
ability to maintain higher prices than those of its competitors, while retaining a much higher market
share; (iii) the strength of AstraZeneca’s patent portfolio; (iv) AstraZeneca’s first-mover status; and
(v) AstraZeneca’s financial strength.
Consistent with past case law, the General Court confirmed that the possession over time of a very
large market share is in itself, save in exceptional circumstances, evidence of the existence of a
The General Court agreed with the European Commission that AstraZeneca’s ability to obtain higher
prices than “me-too” PPIs in its negotiations with national authorities reflected the advantages that it
derived from its first-mover status on a market that it pioneered.
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
This, together with its continued high market share, meant that AstraZeneca was able to maintain
higher revenues than those of its competitors, without the various players in the market (patients,
prescribing doctors, national social security systems and competitors) being able to challenge that
privileged position. It mattered little in the opinion of the General Court that this position was made
possible or favored by social security systems.
The General Court also confirmed that the strong intellectual property rights enjoyed by AstraZeneca
and their exercise, although not abusive, enabled the company to impose significant constraints on
some of its competitors, which in itself is an indicator of a dominant position.
Finally, the court agreed that the commission’s findings regarding AstraZeneca’s financial strength,
although not conclusive in themselves, constituted relevant indicia to support a finding of dominance.The AbusesThe First Abuse: Misleading Representations to the Patent Offices
The General Court’s starting point was that the submission to public authorities of misleading
information liable to lead them into error, and therefore to make possible the grant of an exclusive
right to which an undertaking is not entitled, or to which it is entitled for a shorter period, is a practice
that falls outside the scope of competition on the merits, and that may be particularly restrictive of
Such conduct, therefore, when engaged in by a dominant undertaking, is likely to be abusive.
The first question, therefore, is whether the practice in question, taking into account its context, was
such as to lead the public authorities wrongly to create regulatory obstacles to competition (e.g. by
the unlawful grant of exclusive rights to the dominant undertaking).
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
The limited discretion of public authorities or the absence of any obligation on their part to verify the
accuracy or veracity of the information provided may be relevant factors in this respect.
Although proof of the deliberate nature of conduct liable to deceive the public authorities is not
necessary for the purposes of identifying an abuse, the General Court held that that intention
nonetheless constitutes a relevant factor that may be taken into account by the commission.
In other words, intention is a factor that can play a role in supporting the conclusion that the
undertaking concerned abused a dominant position, but that conclusion should first and foremost be
based on an objective finding that the abusive conduct actually took place.
Finally, once it is established that certain behavior is objectively capable of restricting competition
(directly or indirectly), it is not relevant whether the behavior concerned actually succeeded in
restricting competition — e.g. because certain public authorities did not let themselves be misled, or
because the exclusive rights concerned were revoked, or because they were never enforced.
In this respect, the judgment decision differs from U.S. law, which holds that to support an antitrust
violation, the patent must be shown both to have been awarded by fraud and enforced with the
knowledge of the patent’s fraudulent derivation.The Second Abuse: Deregistration of Marketing Authorizations for Losec Capsules
The General Court found that AstraZeneca had abused its dominant position because it used
regulatory procedures solely to prevent or hinder market entry by competitors, without there being an
objective justification for such conduct or a legitimate interest as part of competition on the merits.
At the relevant time, an application by a generic company for a copy authorization of Losec capsules
under the abridged procedure required the originator’s authorization for that product to be in force in
the country of application at the time the generic copy applied.
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
Deregistration, therefore, stopped such applications from being validated. The General Court
observed, however, that the withdrawal from the market of Losec capsules and the introduction on the
market of Losec tablets were not capable, on their own, of producing the anti-competitive effects
alleged by the commission in this case, namely the creation of regulatory obstacles to market entry by
generic products and to parallel imports of Losec capsules.
The General Court then considered whether AstraZeneca had an objective justification for not
maintaining the marketing authorization given the burden of updating it and the pharmacovigilance
obligations connected with it. The court found that AstraZeneca had failed to demonstrate that the
additional burden would have been so significant that it would have constituted an objective ground
Similar to its findings regarding the first abuse, the court went on to say that once it is established
that AstraZeneca’s conduct was such as to delay or prevent the introduction of generic products and
parallel imports, there was no need to show an intention to cause harm (albeit that on the facts of the
AstraZeneca case the commission did find such intent), nor was it necessary to show the anti-
competitive effects of the deregistrations in practice.
Finally, the General Court found that the existence of an alternative legal basis for generic companies
to obtain copy authorizations through the making of an application based upon published literature
Given the context in which the conduct was implemented, the deregistrations were such as to enable
AstraZeneca to delay, at least temporarily, the significant competitive pressure that generic products
were to exert on it by preventing them to use the quickest and easiest route to market that the EU
However, it also found that the commission had failed to establish to the requisite legal standard that
the deregistration of the Losec capsule marketing authorization was capable of restricting parallel
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
imports of Losec capsules in Denmark and in Sweden. Accordingly, it reduced the total amount of fines
on AstraZeneca from €60 million to €52.5 million.What Are the Implications of This Judgment?
First, new drugs that have the same indication as existing drugs but which through their greater
effectiveness are able to command a significantly higher price and end up being used for different
phases of treatment in one or more countries in the EU are likely to be found to compete in separate
Second, high market shares and high prices over a prolonged period of time combined with a
particularly strong patent portfolio and first-mover status likely will lead to a finding of dominance in
The fact that these elements of dominance may in whole or in part be the result of the regulatory
framework that is applicable to the pharmaceutical industry in Europe does not affect this conclusion,
nor is it relevant that this regulatory framework may prevent the undertaking concerned from
behaving independently on the market.
Finally, this is the first EU case where misuse of regulatory procedures has been found to amount to
an abuse of dominant position under competition rules. It sets precedent that could make it harder for
other pharmaceutical companies to fend off generic competition.
Because of differences between EU and U.S. procedures for obtaining and enforcing patents, and, of
course, sensibilities, we expect the EU and the U.S. to follow similar but not identical paths in the
Marleen Van Kerckhove is a partner and head of Arnold & Porter’s European competition practice andits Brussels office. Asim Varma is a partner in the antitrust/ competition practice group in Arnold &
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx
Porter’s Washington office. Marco Ramondino is a associate in the antitrust/ competition practicegroup in the firm's Brussels office.The opinions expressed are those of the authors and do not necessarily reflect the views of the firm,its clients or Portfolio Media, publisher of Law360.
Arnold & Porter LLP.EU Regulation Procedures In The Pharmaceutical Sector.Competition Law360.July 22 2010.docx

Keystone/AmeriHealth Pharmacy & Therapeutic Committee Meeting Minutes December 8, 2009 Approval of Minutes 0 Against Old Business Committee requested in the October 2009 meeting to have a cardiologist/electrophysiologist to address efficacy, safety, and cost analysis of the Although several doctors were contacted, schedules did not permit them to attend the December

Current prospects for the chemoprevention of prostate cancer ROGER KIRBY, TOM MCNICHOLAS AND JOHN FITZPATRICK Unlike other areas of medicine, such as These data provide compelling evidencehas often been slow to embrace strategiescapable of significantly reducing a man’sno significant difference in the rates offor risk reduction. Currently, urologistsrisk of prostate cancer. Indeed, t